Poolbeg Pharma

About

Poolbeg Pharma plc (AIM: POLB) is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

 

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

 

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. 

Company Type

Precision for Medicine

About

Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.

Contact Precision for Medicine, Oncology and Rare Disease via their website

Company Type
X Account
@Precision4Med

Reprocell

About

REPROCELL offers an end-to-end neoantigen discovery platform tailored for immuno-oncology research, translational programs, and early-phase clinical development. (From Bioserve India, serving worldwide.)

Research Donors

About

Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements. With a diverse community of over 4000 healthy donors, we can meet any donor specification as required by your project.

We collect fresh HLA typed leukopaks, PBMCs, whole blood and other blood derivatives from donors who have been serologically screened and provided full consent for their samples to be used in commercial and genetic research. Delivery is same day of collection (in certain parts of UK) or next day of collection across the rest of UK and Europe. Soon, we will also be able to procure disease biospecimens.

Company Type
X Account
@ResearchDonors

Rosemont Pharmaceuticals

About

Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. 

Company Type

Sareum

About

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

 

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.

Company Type
X Account
@Sareumplc

Scendea

About

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are adept at solving complex issues associated with medicinal product development and offer strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory. Our industry experience is demonstrable, having been involved in over 1,000 development programmes in the US and Europe over the last twenty years. As is our scientific excellence, with a team that includes ex-regulators, high-calibre academics and clinician scientists. Our technical regulatory expertise spans the entire product development spectrum from pre-clinical to marketing authorisation.

Company Type
X Account
@scendea

Science Entrepreneur Club

About

The Science Entrepreneur Club (SEC) is a London based non-profit organisation of curious minds that aims to explore and unite the life science ecosystem by educating, inspiring and connecting. We give scientists, innovators and startups, with a focus on biotech, pharma, medtech, bioengineering, biosustainability or related, a network and a unique platform to showcase their innovative technologies, find investors, meet like-minded people and accelerate their company.

Company Type
X Account
@science_eclub
Keywords

SciTribe

About

Scitribe is a boutique strategic communications consultancy focused on science and technology, including profile-raising, writing and research. It combines professional corporate and scientific communications expertise with lab-based research experience.

Driven by deep understanding and enthusiasm, it applies strategic thinking and listening, combined with a roll-up-your-sleeves & "get it done" know-how, to deliver real value-add output that helps organisations achieve their business and communications objectives.

We apply big-picture thinking and specialist insights to develop strategies that effectively communicate organisations’ impact while ensuring the accurate translation of science for all target audiences and stakeholders. Scitribe provides bespoke, focused and flexible support to provide the clarity, focus, and style that effectively tells our clients’ story through the right channels, to the right audiences.

Company Type
X Account
@drpriyakalia

Serenatis Bio

About
Serenatis Bio is a forward-thinking biotech company focused on revolutionising the treatment of obsessive-compulsive disorder (OCD) - a mental illness that affects hundreds of millions yet remains under-treated, despite its often devastating impact.

Serenatis Bio is advancing three novel drug candidates targeting OCD, each with unique mechanisms of action, through preclinical development. It has successfully closed its pre-seed round, with investors Zinc VC (lead investor), Novaterra Ventures, the Watson Family Office, Medicines Discovery Ventures, P53 Invest and an angel investor. 

Serenatis Bio will be launching a $30M Series A round in the second half of this year in order to go into clinical trials and would like to speak to investors interested in that round. For more information, please contact Nick Sireau, CEO and Co-founder, on nick@serenatisbio.com.
Company Type